Emerald Clinical Trials bestätigt Übergangs- und Kontinuitätsplan für CEO

Emerald Clinical Trials Israel Algeria Bahrain Egypt Iran Iraq Jordan Kuwait Lebanon Libya Morocco Oman Qatar Saudi Arabia Syria Tunisia United Arab Emirates Yemen Angola Botswana Ethiopia Gambia Ghana Guinea-Bissau Kenya Lesotho Liberia Malawi Maldives Mozambique Namibia Nigeria Sierra Leone Somalia South Africa Swaziland Tanzania Uganda Zambia Zimbabwe Singapore

View original content:https://www.prnewswire.com/news-releases/emerald-clinical-trials-bestatigt-ubergangs--und-kontinuitatsplan-fur-ceo-302518815.html